Takeda insider plans sale of 50,582 ADSs
Takeda Pharmaceutical Company Limited has filed a notice for the potential sale of American Depositary Shares (ADSs) under Rule 144.
Rhea-AI Filing Summary
Takeda Pharmaceutical Company Limited has filed a notice for the potential sale of American Depositary Shares (ADSs) under Rule 144. The planned transaction involves 50,582 ADSs, which were acquired on July 1, 2026 through vested Restricted Stock Unit Awards. The ADSs are listed on the NYSE and the broker named for the transaction is Interactive Brokers LLC. The filing characterizes the acquisition as compensation-related and indicates that the securities to be sold are ADSs of Takeda.
Positive
- None.
Negative
- None.
Key Figures
Key Terms
Restricted Stock Unit Awards financial
Compensation financial
Form 144 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What type of securities are involved in Takeda (TAK)'s Form 144 filing?
How many Takeda (TAK) ADSs are covered by this Form 144 notice?
When were the Takeda (TAK) ADSs proposed for sale acquired?
What is the nature of acquisition and sale for the Takeda (TAK) ADSs in this Form 144?
Which broker is handling the potential sale of Takeda (TAK) ADSs under this Form 144?
On which exchange are the Takeda (TAK) ADSs in this Form 144 listed?
AI-generated analysis. How Rhea-AI works. Not financial advice.